RNA-binding proteins RBM-HuR, RBM3 and PODXL expression in urothelial carcinoma of the urinary bladder. Prognostic and clinical implications.

Aim Of The Study: The clinical significance and predictive and prognostic value of HuR, RBM3, and PODXL expression in patients with urothelial bladder cancer (UBC) are not clear yet. The aim of this study was to assess HuR, RBM3 and PODXL expression in muscle invasive and non-muscle invasive UBC tissues, and to investigate the clinicopathological correlations and their predictive and prognostic impact in patients with such type of cancer.

Material And Methods: RBM-HuR, RBM3 and PODXL expression levels were evaluated in 70 patients with urothelial carcinoma by immunohistochemistry. The relationships between their expression, clinicopathological findings and prognostic data were analyzed.

Results: High RBM-HuR expression was related to muscle invasion ( = 0.008), metastasis to lymph nodes ( = 0.007), and presence of blood spread ( = 0.049). High RBM3 expression was associated with lower grade ( = 0.044), absence of distant metastasis ( = 0.025), and absence of lymph node metastasis ( = 0.018). High PODXL expression was significantly associated with advanced tumor stage ( < 0.001), larger tumor size ( = 0.050), lymphovascular invasion ( = 0.006), lymph node metastasis ( = 0.008), higher grade ( = 0.043) and distant metastasis ( = 0.002).Three-year overall survival rate was negatively associated with high expression of both RBM-HuR and PODXL while it was directly correlated with high expression of RBM3 ( = 0.008, 0.009 and 0.015 respectively). High RBM-HuR and PODXL expression and low expression of RBM3 were related to tumor recurrence ( = 0.022, 0.011 and 0.015).

Conclusions: RBM-HuR and PODXL expressions are markers of poor prognosis while RBM3 is a good prognostic marker for urothelial carcinoma of the bladder.